WAKEFIELD, MA, Aug. 12 /CNW/ - NUCRYST Pharmaceuticals, a developer and
manufacturer of medical products that fight infection and inflammation, today
announced its financial results for the second quarter ended June 30, 2008.
NUCRYST also announced today (see separate press release) that its Board of
Directors has authorized a program for the Company to repurchase up to 900,000
shares of its outstanding common stock.
